Boehringer Ingelheim exercises option on second OGAP oncology target

Family-owned German pharma major Boehringer Ingelheim has exercised an option to receive exclusive rights to an oncology target from its discovery collaboration with privately-held UK biotech firm Oxford BioTherapeutics.

The target was discovered using Oxford BioTherapeutics’ proprietary OGAP system, which incorporates one of the world’s largest proprietary proteomic databases, integrating clinical, experimental and expression data.

This represents the second option exercised under the companies’ oncology target discovery and validation collaboration established in 2013.  Under the terms of the agreement, Boehringer Ingelheim will be responsible for the future development and commercialization of antibody products to the target. Oxford BioTherapeutics will receive development and regulatory milestone payments, and royalties on any future product sales.